Development of semi-automated system for preparation of 188Re aqueous solutions of high and reproducible activity concentrations

Jäckel, B.; Cripps, R.; Güntay, S.; Bruchertseifer, H.

doi:10.1016/j.apradiso.2005.04.009

Cited by 23 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, personnel exposures may be reduced by automation or semiautomation of generator operation. 70,71 The consequences of the high activity levels of such a high beta-energy emitting radionuclide should not be underestimated, and the radiological protection issues required to minimize radiation dose to personnel are important in using this generator system. In addition to the bremsstrahlung radiation from interaction with the high energy 2.12 MeV beta particle, as shown in Figure 6, there are also several highenergy gamma-rays emitted by 188 Re that complicate the shielding requirements for and gamma camera imaging of this isotope.…”

Section: Radiation Safety and Shielding Requirementsmentioning

confidence: 99%

Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Jeong

Knapp

2008

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Section: Radiation Safety and Shielding Requirementsmentioning

confidence: 99%

Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Jeong

Knapp

2008

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

“…The standard alumina-based generator is eluted with saline at a slow flow-rate of typically 1–2 mL/min., with the volume based on the size of the generator (i.e., “void volume”) to insure complete removal of the 188 Re bolus. Some institutions have instituted the use of semi- or totally-automated elution systems (46–48). These methods have helped move use of the generator forward, and are important to insure reproducible results and reduce the user radiation burden.…”

Section: Re Productionmentioning

confidence: 99%

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

et al. 2019

View full text Add to dashboard Cite

Rhenium-188 ( 188 Re) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-life, which has been shown to be a very attractive candidate for use in therapeutic nuclear medicine. The high beta emission has an average energy of 784 keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is efficient for imaging and for dosimetric calculations. These key characteristics identify 188 Re as an important therapeutic radioisotope for routine clinical use. Moreover, the highly reproducible on-demand availability of 188 Re from the 188 W/ 188 Re generator system is an important feature and permits installation in hospital-based or central radiopharmacies for cost-effective availability of no-carrier-added (NCA) 188 Re. Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent a “theranostic pair.” Thus, preparation and targeting of 188 Re agents for therapy is similar to imaging agents prepared with 99m Tc, the most commonly used diagnostic radionuclide. Over the last three decades, radiopharmaceuticals based on 188 Re-labeled small molecules, including peptides, antibodies, Lipiodol and particulates have been reported. The successful application of these 188 Re-labeled therapeutic radiopharmaceuticals has been reported in multiple early phase clinical trials for the management of various primary tumors, bone metastasis, rheumatoid arthritis, and endocoronary interventions. This article reviews the use of 188 Re-radiopharmaceuticals which have been investigated in patients for cancer treatment, demonstrating that 188 Re represents a cost effective alternative for routine clinical use in comparison to more expensive and/or less readily available therapeutic radioisotopes.

show abstract

“…However, due to the low specific activity of 188 W, the 188 Re obtained from 188 W/ 188 Re generators is eluted with low radioactivity concentration. For this reason, it often needs an additional concentration step for therapeutic applications [ 11 , 12 , 13 , 14 , 15 , 16 ]. Alternative pathways such as 188 W/ 188 Re gel generators based on zirconium or titanium wolframate, have also been exploited [ 17 , 18 ], however nowadays most of the commercial 188 W/ 188 Re generators are based on alumina as sorbent on the column.…”

Section: Rhenium-188mentioning

confidence: 99%

188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy

2017

View full text Add to dashboard Cite

The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188Re is readily available from an 188W/188Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications.

show abstract

Development of semi-automated system for preparation of 188Re aqueous solutions of high and reproducible activity concentrations

Cited by 23 publications

References 13 publications

Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy

Contact Info

Product

Resources

About